

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT TERMINATION OF MEMORANDUM OF UNDERSTANDING ON POSSIBLE COOPERATION

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business development of the Group.

Reference is made to the announcement of the Company dated 29 July 2024 in relation to the voluntary announcement of a non-legally binding Memorandum of Understanding on Possible Cooperation entered into with Shanxi Ningle Pharmaceutical Logistics Co., Ltd. (山西寧樂醫藥物流有限公司) (the “**Shanxi Ningle**”) (the “**Announcement**”). Unless otherwise specified, the terms used in this announcement shall have the same meanings as those defined in the Announcement.

TERMINATION OF MEMORANDUM OF UNDERSTANDING ON POSSIBLE COOPERATION

Following the non-legally binding Memorandum of Understanding on Possible Cooperation with Shanxi Ningle entered into on 29 July 2024 and the voluntary announcement, the Company, after conducting further due diligence and gaining a detailed understanding of the background of Shanxi Ningle, considered that the credibility of the information and financial data provided by Shanxi Ningle is doubtful, which reflects that Shanxi Ningle failed to satisfy the basic minimum requirements for cooperation with the Company. Furthermore, since the date of entering into the non-legally binding Memorandum of Understanding on Possible Cooperation with Shanxi Ningle, neither the Company nor Shanxi Ningle has reached any offer, implemented any cooperation plan, or authorised any person to act on behalf of the Company or make statements, and will not do so in the future. It is hereby declared that all the dealings of Shanxi Ningle, including but not limited to its subsidiaries, connected companies, holding companies or shareholders, all of its employees and related and authorised persons, shall be entirely of no concern to the Group. In view of this, the Memorandum of Understanding on Possible Cooperation will be immediately terminated. The Company expresses its deep regret to shareholders for any inconvenience that may be caused by the termination.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 2 September 2024

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.